1
|
Shao Z, Tong Z, Liu Q, Li W, Cai L, Shen K, Li H, Wang C, Yang J, Song Z, Wang S, Luo T, Zhao W, Wang H, Pan Y, Nie J, Zeng X, Bai Y, Chiang W, Guarnaccia V, Bi Y, Xu B. Initial ribociclib plus endocrine therapy for HR+/HER2- advanced breast cancer in pre- and postmenopausal Chinese women: Primary results from a phase 2 randomized study. Cancer Med 2024; 13:e7408. [PMID: 39136200 PMCID: PMC11320080 DOI: 10.1002/cam4.7408] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2024] [Accepted: 06/07/2024] [Indexed: 08/15/2024] Open
Abstract
AbstractBackgroundThe MONALEESA‐7 and ‐2 phase 3 randomized trials demonstrated a statistically significant progression‐free survival (PFS) and overall survival (OS) benefit with initial ribociclib + endocrine therapy (ET) versus placebo + ET in pre‐ and postmenopausal patients with hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (ABC), respectively. Similar trends were observed in Asian subgroup analyses. This phase 2 bridging study of initial ET + ribociclib enrolled pre‐ and postmenopausal patients with HR+/HER2– ABC from China and was conducted to demonstrate consistency of PFS results in a Chinese population relative to the global MONALEESA‐7 and ‐2 studies.MethodsPatients were randomized (1:1) to ET (nonsteroidal aromatase inhibitor + goserelin for premenopausal patients; letrozole for postmenopausal patients) + either ribociclib or placebo. The primary endpoint was investigator‐assessed PFS.ResultsAs of April 25, 2022, the median follow‐up was 34.7 months in both cohorts. In the premenopausal cohort, median PFS was 27.6 months in the ribociclib arm (n = 79) versus 14.7 months in the placebo arm (n = 77) (hazard ratio 0.67 [95% CI: 0.45, 1.01]). In the postmenopausal cohort, median PFS was not reached in the ribociclib arm versus 18.5 months in the placebo arm (n = 77 in each arm) (hazard ratio 0.40 [95% CI: 0.26, 0.62]). Data also suggested improvements in secondary efficacy endpoints, although OS data were not mature. The safety profile in this population was consistent with that in global studies.ConclusionsThese data demonstrate a favorable benefit–risk profile for ribociclib + ET in Chinese patients.
Collapse
Affiliation(s)
- Zhimin Shao
- Fudan University Shanghai Cancer CenterShanghaiChina
| | - Zhongsheng Tong
- Tianjin Medical University Cancer Institute and HospitalTianjinChina
| | - Qiang Liu
- Sun Yat‐Sen Memorial HospitalSun Yat‐Sen UniversityGuangzhouChina
| | - Wei Li
- The First Bethune Hospital of Jilin UniversityChangchunChina
| | - Li Cai
- Harbin Medical University Cancer HospitalHarbinChina
| | - Kunwei Shen
- RuiJin Hospital Shanghai Jiao Tong University School of MedicineShanghaiChina
| | - Huiping Li
- Department of Breast Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing)Peking University Cancer Hospital & InstituteBeijingChina
| | - Chuan Wang
- Affiliated Union Hospital of Fujian Medical UniversityFuzhouChina
| | - Jin Yang
- The 1st Affiliated Hospital of Xi'an Jiaotong UniversityXi'AnChina
| | - Zhenchuan Song
- Fourth Hospital of Hebei Medical UniversityShijiazhuangChina
| | - Shui Wang
- Jiang Su Province RenMin HospitalNanjingChina
| | - Ting Luo
- West China HospitalSichuan UniversityChengduChina
| | - Wenhe Zhao
- Sir Run Run Shaw Hospital/Zhejing University School of MedicineHangzhouChina
| | - Haibo Wang
- The Affiliated Hospital of Qingdao UniversityQingdaoChina
| | | | - Jianyun Nie
- Yunnan Provincial Cancer HospitalKunmingChina
| | | | - Yanqing Bai
- Novartis Global Drug DevelopmentBeijingChina
| | - Wendy Chiang
- Novartis Pharmaceuticals CorporationEast HanoverNew JerseyUSA
| | | | - Yu Bi
- Novartis Global Drug DevelopmentBeijingChina
| | - Binghe Xu
- National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical CollegeBeijingChina
| |
Collapse
|
2
|
Yu Y, Xu Z, Zhou H, Xu R, Xu J, Liu W, Wu Y, Qiu Y, Zhang G, Huang X, Chen Y. RBP7 functions as a tumor suppressor in HR + breast cancer by inhibiting the AKT/SREBP1 pathway and reducing fatty acid. Cancer Cell Int 2024; 24:118. [PMID: 38553715 PMCID: PMC10979609 DOI: 10.1186/s12935-024-03299-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2023] [Accepted: 03/08/2024] [Indexed: 04/02/2024] Open
Abstract
BACKGROUND Increasing evidence proves that RBP7 plays a significant role in breast cancer (BC). The present study was aimed to investigate the mechanism of RBP7. METHODS Western Blotting and qRT-PCR were performed for evaluating the expression levels. CCK8, colony forming, xenograft mouse model, wound healing and transwell assays were conducted to examine cell ability of proliferation, invasion and migration. Nile red staining and Oil red O staining were used for testing the lipid. RESULTS RBP7 was related to overall survival (OS) in patients with HR + BC. RBP7 protein was significantly decreased in HR + BC tissues and cells. RBP7 suppressed HR + BC cell proliferation in vitro and in vivo, and inhibited migration and invasion. RBP7 reduced fatty acid in HR + BC cells by inhibiting the AKT/SREBP1 pathway. CONCLUSIONS RBP7 may function as a tumor suppressor in HR + BC by inhibiting the AKT/SREBP1 pathway and reducing fatty acid.
Collapse
Affiliation(s)
- Yue Yu
- Department of General Surgery, The First Affiliated Hospital of Soochow University, NO. 899, Pinghai Road, Suzhou, 215006, China
| | - Zhihua Xu
- Department of General Surgery, The First Affiliated Hospital of Soochow University, NO. 899, Pinghai Road, Suzhou, 215006, China
| | - Hao Zhou
- Department of General Surgery, The First Affiliated Hospital of Soochow University, NO. 899, Pinghai Road, Suzhou, 215006, China
| | - Ruyan Xu
- Jiangsu Institute of Clinical Immunology, The First Affiliated Hospital of Soochow University, Suzhou, China
| | - Jia Xu
- Jiangsu Institute of Clinical Immunology, The First Affiliated Hospital of Soochow University, Suzhou, China
| | - Wenjun Liu
- Jiangsu Institute of Clinical Immunology, The First Affiliated Hospital of Soochow University, Suzhou, China
| | - Yuxin Wu
- Department of General Surgery, The First Affiliated Hospital of Soochow University, NO. 899, Pinghai Road, Suzhou, 215006, China
| | - Yue Qiu
- Department of General Surgery, The First Affiliated Hospital of Soochow University, NO. 899, Pinghai Road, Suzhou, 215006, China
| | - Guangbo Zhang
- Jiangsu Institute of Clinical Immunology, The First Affiliated Hospital of Soochow University, Suzhou, China
| | - Xue Huang
- Jiangsu Institute of Clinical Immunology, The First Affiliated Hospital of Soochow University, Suzhou, China.
| | - Yan Chen
- Department of General Surgery, The First Affiliated Hospital of Soochow University, NO. 899, Pinghai Road, Suzhou, 215006, China.
| |
Collapse
|
3
|
Zhang Y, Chen W, Chen S, Yang Q, Ouyang Z. Early Application of Palbociclib Plus Endocrine Therapy in HR+/HER2- Metastatic Breast Cancer: A Better Choice Based on Data From the Chinese Population. Technol Cancer Res Treat 2022; 21:15330338221132926. [PMID: 36310472 PMCID: PMC9623362 DOI: 10.1177/15330338221132926] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
Background: Palbociclib is the most widely used cyclin-dependent kinase 4/6 inhibitor in China, but its early application efficacy on Chinese metastatic breast cancer (MBC) patients was reported deficiently. Methods: Between February 2019 to December 2021, 95 female hormone receptor-positive (HR+)/human epidermal growth factor receptor-2 negative (HER2-) patients with MBC received palbociclib combined with AI or fulvestrant were retrospectively analyzed in our center. The primary outcome was progression-free survival (PFS). The objective response rate and clinical benefit rate (CBR) were evaluated. Results: The median follow-up period was 15 months (range from 2 to 37). Palbociclib performed superiorly when applicated in first-and-second line therapy than in later lines (P = .002). Palbociclib combined with AI or fulvestrant had a median PFS of 34 months (95% confidence interval [CI] = 6.87-61.13) and 12 months (95%CI = 7.76-16.24), respectively. Univariate subgroup analysis showed that the previous history of salvage chemotherapy (P = .015) and the presence of liver metastases (P < .001) significantly affected the efficacy of palbociclib. Despite the existence of liver metastases and primary endocrine resistance, which are two independent predictors of poor prognosis, early application of palbociclib in advanced stage can bring further benefits to these two groups of patients, rather than choosing salvage chemotherapy in the first place. Conclusion: Palbociclib combined with endocrine therapy has a favorable efficacy and acceptable toxicity in HR+/HER2- Chinese MBC patients. Better performance can be seen when palbociclib was applicated in the early stage.
Collapse
Affiliation(s)
- Yusi Zhang
- The First Affiliated Hospital of
Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian,
China
| | - Wenlin Chen
- The First Affiliated Hospital of
Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian,
China
| | - Shuanglong Chen
- The First Affiliated Hospital of
Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian,
China
| | - Qingmo Yang
- The First Affiliated Hospital of
Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian,
China,Qingmo Yang, MD, Department of Breast
Surgery, The First Affiliated Hospital of Xiamen University, School of Medicine,
Xiamen University, Xiamen Fujian 361003, China.
| | - Zhong Ouyang
- The First Affiliated Hospital of
Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian,
China,Zhong Ouyang, MD, Department of Breast
Surgery, The First Affiliated Hospital of Xiamen University, School of Medicine,
Xiamen University, Xiamen Fujian 361003, China.
| |
Collapse
|